http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103966352-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2014-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103966352-B |
| titleOfInvention | PCA3, CST1 and CST4 are at the application prepared in prostate cancer marker and test kit thereof |
| abstract | The invention discloses PCA3, CST1 and CST4 at the application prepared in prostate cancer marker and test kit thereof, PCA3, CST1 and CST4 are combined for diagnosing and indicating the specificity of prostate cancer and highly sensitive in only using PCA3 as mark; The invention also discloses the test kit of the above-mentioned mark of joint-detection, its test kit is easy to use, can directly collect urine to detect, do not need to gather serum, the sampling reducing patient is painful, and has the good He highly sensitive feature of specificity, can be used in prostate cancer diagnosis, curative effect evaluation in therapeutic process and the monitoring of the transfer and relapse after treating thereof, provide guidance for doctor carries out intervention in advance. |
| priorityDate | 2014-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 80.